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Adult body mass index (BMI) has been associated with ovarian cancer risk, but few studies have examined body size earlier in life. We
prospectively examined associations of body fatness at ages 5 and 10, BMI at age 18, height, and birthweight with risk of epithelial
ovarian cancer in the Nurses’ Health Study (NHS: 110311 women, 735 cases) and Nurses’ Health Study II (NHSII: 113059 women,
137 cases). Cox proportional hazards regression was used to estimate relative risks (RRs) and 95% confidence intervals (CIs). There
was a weak inverse association between average body fatness at ages 5 and 10 and risk in the NHS (RR for heaviest vs most
lean¼0.81, 95% CI: 0.53–1.24, P for trend¼0.04) and a nonsignificant positive association in the NHSII (RR¼2.09, 95% CI:
0.98–4.48, P for trend¼0.10), possibly due to differences in age and menopausal status. Height was positively associated with risk in
both cohorts (RR for X1.75 vs o1.6m¼1.43, 95% CI: 1.05–1.96, P for trend¼0.001). Body mass index at the age of 18 years and
birthweight were not associated with risk. Further research should examine the biological mechanisms underlying the observed
associations.
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Overweight and obesity have been associated with risk of cancer in
women (Calle and Kaaks, 2004), but the findings for ovarian
cancer are inconclusive. Some epidemiological studies have
observed weak to moderate positive associations between adult
body mass index (BMI) and ovarian cancer risk; others have found
no association (Olsen et al, 2007). One potential explanation is that
the timing of overweight and obesity during the lifecourse may be
important. Although most studies have examined ovarian cancer
risk in relation to recent BMI, studies examining BMI earlier in life,
during late adolescence or young adulthood, have observed
stronger positive associations (Fairfield et al, 2002; Engeland
et al, 2003; Lubin et al, 2003; Anderson et al, 2004). Body fatness
during childhood and early adolescence has been associated with
breast cancer risk, independent of adult BMI (Berkey et al, 1999;
Baer et al, 2005), suggesting that adiposity at young ages may affect
risk of hormone-related cancers. Furthermore, there is evidence
that height, a marker of early childhood growth and nutrition, is
associated with ovarian cancer risk (Rodriguez et al, 2002;
Engeland et al, 2003; Schouten et al, 2003, 2008), indicating that
early life may be a critical time period for ovarian cancer initiation.
Therefore, we prospectively examined the associations of body
size in early life – including body fatness at ages 5 and 10 years,
BMI at the age of 18 years, birthweight, and height – with risk of
epithelial ovarian cancer among participants in two large cohort
studies, the Nurses’ Health Study (NHS) and the NHSII.
MATERIALS AND METHODS
Study design and population
The NHS began in 1976 and the NHSII in 1989, when 121700 and
116609 US female registered nurses, respectively, completed a
mailed questionnaire about their lifestyle factors, health beha-
viours, and medical histories. Follow-up questionnaires have been
sent to participants every 2 years since enrolment. Incident cases
of epithelial ovarian cancer were reported on the biennial
questionnaires through 2004 (NHS) and 2005 (NHSII). A
gynaecologic pathologist reviewed the pathology reports and
medical records to confirm the diagnosis and identify histological
type, subtype, morphology, and stage (Tworoger et al, 2008).
Assessment of body size in early life and other covariates
Participants recalled their body fatness (also called ‘somatotype’)
at ages 5 and 10 years using a nine-level figure drawing, where level
1 represents the most lean and level 9 represents the most
overweight (Figure 1) (Stunkard et al, 1983). Among participants
in the Third Harvard Growth Study, Pearsons correlations between
recalled somatotype and measured BMI were 0.60 for the age
of 5 years and 0.70 for the age of 10 years (Must et al, 1993). We
averaged each participant’s reported somatotypes at ages 5 and
10 years to obtain an estimate of childhood body fatness. The
levels 5 and above were combined in the analysis because of
small numbers of participants in these categories.
Women reported their weight at the age of 18 years and their
current height at enrolment; these were used to calculate BMI at
the age of 18 years in kgm
 2. In a sample of NHSII participants,
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the age of 18 years was 0.87, and for BMI at the age of 18 years was
0.84 (Troy et al, 1995). Categories for BMI at the age of 18 years
and height were chosen based on their distributions and
previously used cutpoints.
Participants recalled their birthweight as o5.5, 5.5–6.9, 7.0–8.4,
8.5–9.9, and X10 pounds. The two highest categories (8.5 pounds
and higher) were combined in the analysis to increase power. In a
NHSII validation study (Troy et al, 1996), the correlation between
self-reported birthweight and that obtained from state birth
records was 0.74.
Age and other covariates were assessed on the questionnaires
throughout the study.
Statistical analysis
Participants contributed person-time from baseline (the ques-
tionnaire year that the exposure of interest was assessed) until the
date of ovarian cancer diagnosis, report of other cancer (except
nonmelanoma skin cancer), death, or 31 May 2004 (NHS) or 31
May 2005 (NHSII), whichever occurred sooner. We excluded
women reporting a previous diagnosis of cancer except non-
melanoma skin cancer and those with a history of bilateral
oophorectomy or pelvic irradiation. For analyses focusing on each
individual body size measure, we excluded women who were
missing data for that measure. The years of assessment, numbers
of eligible participants and cases, and total numbers of person-
years available for each analysis are shown in Table 1.
Cox proportional hazards models stratified by age in months
and 2-year questionnaire cycle were used to estimate relative risks
(RRs) and 95% confidence intervals (CIs), adjusting for ovarian
cancer risk factors. Tests for linear trend were conducted by
including each body size measure in a model either as an ordinal
variable (childhood body fatness, birthweight) or as a continuous
variable with values equal to the category medians (BMI at the age
of 18 years, height).
We first conducted the analyses within the NHS and NHSII
separately. We then evaluated heterogeneity in the estimates by
cohort (DerSimonian and Laird, 1986). We used interaction terms
and stratified analyses to assess effect modification by menopausal
status, age, and common ovarian cancer risk factors. Separate
models were run for invasive cases alone and by histological type
(serous/poorly-differentiated, endometrioid, mucinous).
RESULTS
Most adult characteristics were not associated with early life body
size (Table 2). In both cohorts, greater body fatness during
childhood and BMI at the age of 18 years were associated with
earlier menarche and higher current BMI, and taller height was
associated with later menarche. In the NHS, women with greater
childhood body fatness and taller women were slightly younger at
baseline, and women who were heavier in childhood and at the age
of 18 years were slightly less likely to use postmenopausal
hormones. In the NHSII, women with greater childhood body
fatness, greater BMI at the age of 18 years, and taller height were
less likely to be parous, and those with greater BMI at the age of 18
years also had shorter duration of oral contraceptive use.
In the NHS, greater body fatness at ages 5 and 10 years were
associated with decreased risk of ovarian cancer (Table 3), although
the association was only significant for the age of 10 years
(RR for level X5 vs level 1¼0.69, 95% CI: 0.48–0.99,
P for trend¼0.01). Averaging ages 5 and 10 years, the RR for
childhood body fatness level X5 compared to level 1 was 0.81
(95% CI: 0.53–1.24, P for trend¼0.04). In contrast, there was some
suggestion of a positive association for average childhood body
fatness in the NHSII (RR for level X5 vs level 1¼2.09, 95% CI:
0.98–4.48), although this was not statistically significant (P for
trend¼0.10) (Table 3). The associations for body fatness at ages 5
and 10 years individually and average childhood body fatness were
significantly different by cohort (P for heterogeneity¼0.03, 0.01,
Figure 1 Figure drawing used to assess body fatness at ages 5 and 10 years.
Table 1 Timing of body size assessments and numbers of participants, cases, and person-years included in each analysis, by study population
Body size measure Cohort
a Year assessed
b No. of participants No. of cases No. of person-years
Body fatness at ages 5 and 10 years NHS 1988 64876 372 888845
NHSII 1989 110274 131 1614085
Body mass index at the age of 18 years NHS 1980 84643 581 1680079
NHSII 1989 112119 136 1640636
Height NHS 1976 110311 735 2528901
NHSII 1989 113059 137 1654409
Birthweight NHS 1992 49321 226 521364
NHSII 1991 77952 88 1016804
aThe Nurses’ Health Study (NHS) began in 1976 and had 121700 participants at enrolment, 30–55 years of age. The Nurses’ Health Study II (NHSII) began in 1989 and had
116609 participants at enrolment, 25–42 years of age.
bThe year when each body size measure was assessed defined the baseline for that analysis; follow-up was through
31 May 2004 for NHS and 31 May 2005 for NHSII.
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not significantly associated with risk in either cohort.
One major difference between the NHS and NHSII cohorts is the
menopausal status of participants when childhood body size was
assessed (NHS: 32% premenopausal in 1988, NHSII: 99%
premenopausal in 1989). To explore whether this could explain
the observed difference in the association of childhood body
fatness with risk, we combined the data from both cohorts and
stratified by menopausal status in the cycle before diagnosis
(Table 4). There was some suggestion of a weak positive
association between childhood body fatness and risk of ovarian
cancer in premenopausal women (pooled RR for level X5 vs level
1¼1.38, 95% CI: 0.70–2.71, P for trend¼0.92) and a weak inverse
association in postmenopausal women (comparable RR¼0.85,
95% CI: 0.54–1.31, P for trend¼0.09), although neither these nor
the interaction with menopausal status (P¼0.37) were statistically
significant. Results for BMI at the age of 18 years were similar in
premenopausal women, but there was no evidence of an inverse
association in postmenopausal women (P for interaction¼0.11).
Alternatively, the observed variation in the associations for
childhood body fatness could be explained by age differences
between participants in the two cohorts (NHS: mean age¼54.3 in
1988, NHSII: mean age¼34.3 in 1989); therefore, we conducted a
preliminary analysis combining both cohorts and stratifying by
age, while adjusting for menopausal status. There were nonsigni-
ficant positive associations between childhood body fatness and
ovarian cancer risk in women less than the age of 50 years (pooled
RR for level X5 vs level 1¼1.77, 95% CI: 0.85–3.69,
P for trend¼0.39) and in women between the ages 50 and 59
years (comparable RR¼1.30, 95% CI: 0.64–2.65, P for trend¼
0.34), whereas the association was inverse in women at the age of
60 years and older (comparable RR¼0.67, 95% CI: 0.39–1.16,
P for trend¼0.01). The interaction between childhood body
fatness and age was statistically significant (P¼0.001). When we
jointly stratified by age and menopausal status, the positive
association between childhood body fatness and ovarian cancer
risk appeared stronger in premenopausal women under the age of
45 years (pooled RR for childhood body fatness level X5 vs level
1¼2.51, 95% CI: 0.94–6.73) than in those at the age of 45 years
and older (comparable RR¼0.83, 95% CI: 0.30–2.28). Conversely,
the inverse association in postmenopausal women was stronger
among those at the age of 60 years and older (pooled RR for
Table 2 Age-standardised
a characteristics in 1988 (Nurses’ Health Study) and 1989 (Nurses’ Health Study II) by body size measures and study population
Average childhood
body fatness
b
BMI at the age of
18 years, kgm
 2 Height, m Birthweight, lbs
1 X5 o20 X25 o1.6 X1.75 o5.5 X8.5
Nurses’ Health Study (NHS)
Sample size at baseline
c 19371 4633 29077 8212 24877 5165 3312 6868
Means
Age (years) 55.4 53.9 54.4 54.6 55.0 53.8 53.6 54.9
Age at menarche (years) 12.8 12.2 12.8 12.2 12.3 12.9 12.4 12.6
Parity (among parous women) 3.2 3.0 3.1 3.1 3.2 3.0 3.1 3.1
Duration of oral contraceptive use (months) 24.6 24.0 25.2 23.2 22.9 23.2 25.9 24.7
Current body mass index (kgm
 2) 24.4 28.1 23.4 30.8 25.7 25.1 25.5 26.1
Percentages
Parous 93.0 92.3 92.5 90.8 92.4 90.5 92.6 92.5
Premenopausal 31.6 31.7 27.8 27.1 25.2 25.5 34.2 33.3
Postmenopausal 68.2 68.2 70.1 70.6 69.3 69.7 65.0 65.8
Family history of ovarian cancer
d 2.6 2.8 2.5 2.9 2.2 2.7 3.0 2.6
History of tubal ligation 17.4 17.9 17.0 18.3 17.0 15.5 19.3 18.2
Current postmenopausal hormone user
(among postmenopausal women)
25.3 22.3 27.8 20.9 25.2 26.8 23.4 24.8
Nurses’ Health Study II (NHSII)
Sample size at baseline
c 19220 6984 44078 11745 21440 8922 2834 11467
Means
Age (years) 34.6 34.8 34.3 34.3 34.5 34.0 35.0 33.7
Age at menarche (years) 12.8 12.0 12.7 12.0 12.2 12.7 12.3 12.5
Parity (among parous women) 2.1 2.0 2.1 2.0 2.0 2.0 2.1 2.1
Duration of oral contraceptive use (months) 46.9 43.0 45.6 39.3 42.7 44.1 45.7 43.3
Current body mass index (kgm
 2) 22.1 27.6 21.4 31.3 24.3 23.9 24.1 24.5
Percentages
Parous 69.9 62.5 70.8 56.7 70.2 64.8 68.0 67.3
Premenopausal 99.0 98.6 99.0 98.3 98.7 99.1 98.7 98.8
Family history of ovarian cancer
d 1.5 1.9 1.5 1.8 1.5 1.6 1.8 1.5
History of tubal ligation 16.5 16.1 15.1 14.9 17.3 13.6 17.1 14.5
aAll factors except age were age-standardised in 5-year intervals for each cohort.
bAverage childhood body fatness was calculated by taking the average of each participant’s body
fatness at ages 5 and 10 years, using a nine-level figure drawing.
cBaseline for each analysis was the year when the body size measure was assessed (see Table 1).
dMother or sister
had ovarian cancer according to the participant’s response on the questionnaire; family history was evaluated using data from 1992 for NHS and 1993 for NHSII because it was
not available in previous cycles.
Early body size and ovarian cancer
HJ Baer et al
1918
British Journal of Cancer (2008) 99(11), 1916–1922 & 2008 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
ychildhood body fatness level X5 vs level 1¼0.67, 95% CI: 0.39–
1.16) than in those younger than the age of 60 years (comparable
RR¼1.63, 95% CI: 0.73–3.66).
Additional adjustment for current BMI as a continuous variable
had virtually no impact on the childhood body fatness associations
in the NHS or for postmenopausal women overall (data not
shown). However, the positive association for childhood body
fatness in the NHSII and in premenopausal women was attenuated
when including current BMI (RR for childhood body fatness level
X5 vs level 1 in premenopausal women¼1.23, 95% CI: 0.61–2.47,
P for trend¼0.73). Adjustment for age at menarche had no
substantial impact on the associations (data not shown).
Height was positively associated with ovarian cancer risk in
both cohorts (pooled RR for X1.75 vs o1.6m¼1.43, 95% CI:
1.05–1.96, P for trend¼0.001), and the test for heterogeneity
was not significant (P¼0.22); however, the association appeared
stronger in the NHSII (comparable RR¼2.35, 95% CI: 1.19–4.63,
P for trend¼0.01) than in the NHS (comparable RR¼1.27,
95% CI: 0.88–1.82, P for trend¼0.01) (Table 5). The positive
association was slightly stronger among premenopausal than
postmenopausal women, although there were no significant
interactions with menopausal status or age (data not shown).
Birthweight was not significantly associated with risk of ovarian
cancer in either cohort.
The observed associations for body size in early life were
similar for invasive cases alone and by histological type,
although these analyses were limited by small case numbers. No
significant interactions were observed between any of the body size
measures and parity, oral contraceptive use, postmenopausal
hormone use, or family history of breast or ovarian cancer
(data not shown).
DISCUSSION
Results from this study indicate that body size in early life may be
related to the risk of epithelial ovarian cancer. Body fatness during
childhood was associated with ovarian cancer risk, although the
association differed by cohort; greater body fatness at ages 5 and
10 years was associated with a slightly lower risk among NHS
women, but a suggestion of an increased risk among NHSII
women. These differences could be explained by differences in the
menopausal status or age of participants. Body mass index at the
age of 18 years and birthweight were not associated with risk;
however, height was positively associated with risk.
To our knowledge, this is the first study to investigate the
association of childhood fatness with ovarian cancer risk. Previous
studies have examined the relation between overweight and obesity
Table 3 Multivariate
a relative risks (RR) and 95% confidence intervals (CI) of epithelial ovarian cancer according to childhood body fatness and BMI at
the age of 18 years, by study population
Nurses’ Health Study (NHS) Nurses’ Health Study II (NHSII)
Cases Person-years Multivariate
a RR (95% CI) Cases Person-years Multivariate
a RR (95% CI)
Body fatness at the age of 5 years
1 169 362320 1.0 (REF) 27 397883 1.0 (REF)
2 89 205923 0.97 (0.75–1.26) 36 513243 1.12 (0.68–1.85)
3 54 155820 0.78 (0.58–1.07) 38 385284 1.48 (0.90–2.42)
4 32 96839 0.74 (0.50–1.08) 17 206119 1.18 (0.64–2.17)
X5 28 67943 0.87 (0.58–1.29) 13 111557 1.65 (0.85–3.20)
P for trend
b 0.11 0.12
P for heterogeneity
c¼0.03
Body fatness at the age of 10 years
1 143 274838 1.0 (REF) 18 301794 1.0 (REF)
2 102 233863 0.87 (0.67–1.13) 32 495385 1.16 (0.65–2.08)
3 50 158127 0.64 (0.46–0.88) 36 365516 1.76 (1.00–3.11)
4 41 116397 0.72 (0.51–1.02) 29 255624 1.91 (1.06–3.45)
X5 36 105620 0.69 (0.48–0.99) 16 195766 1.30 (0.66–2.56)
P for trend
b 0.01 0.12
P for heterogeneity
c¼0.01
Average body fatness at the ages 5 and 10 years
d
1 135 263830 1.0 (REF) 15 279639 1.0 (REF)
1.5–2 107 241430 0.90 (0.70–1.17) 35 495350 1.44 (0.78–2.64)
2.5–3 61 173145 0.73 (0.54–0.99) 37 405487 1.80 (0.98–3.28)
3.5–4.5 43 147540 0.61 (0.43–0.86) 32 332410 1.79 (0.97–3.32)
X5 26 62901 0.81 (0.53–1.24) 12 101199 2.09 (0.98–4.48)
P for trend
b 0.04 0.10
P for heterogeneity
c¼0.01
BMI at the age of 18 years, kgm
 2
o20 204 578036 1.0 (REF) 38 645713 1.0 (REF)
20–20.9 95 314831 0.89 (0.69–1.13) 29 288710 1.79 (1.10–2.91)
21–22.9 147 427126 1.02 (0.82–1.26) 38 366025 1.87 (1.19–2.95)
23–24.9 76 200613 1.10 (0.84–1.43) 14 169776 1.46 (0.79–2.71)
X25 59 159473 1.06 (0.79–1.41) 17 170411 1.57 (0.88–2.79)
P for trend
e 0.46 0.13
P for heterogeneity
c¼0.32
aMultivariate analyses adjusted for age (continuous), parity (continuous), duration of oral contraceptive use (continuous), tubal ligation history (yes/no), and height (o1.6, 1.6 to
o1.65, 1.65 to o1.7, 1.7 to o1.75, and X1.75m).
bP value from multivariate model with body fatness as continuous variable.
cP for heterogeneity by cohort assessed using
the DerSimonian and Laird random effects model.
dAverage childhood body fatness calculated by taking the average of each participant’s body fatness at the ages 5 and 10 years.
eP value from multivariate model with BMI at the age of 18 years modelled as medians of categories.
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results (Olsen et al, 2007). One possible reason for these
inconsistencies pertains to the timing of body size assessment.
Several studies have observed stronger associations for BMI in
adolescence or young adulthood than for recent BMI (Engeland
et al, 2003; Anderson et al, 2004). The results from our study
indicate that body size at even younger ages may be an important
predictor of ovarian cancer risk.
A second potential explanation is that the relation between body
size at young ages and ovarian cancer risk may differ by
menopausal status or age. In a pooled analysis of 12 cohorts,
BMI at baseline was not associated with risk overall or among
postmenopausal women, but there was a positive association in
premenopausal women (Schouten et al, 2008). Our findings also
suggest that the positive association for childhood body fatness
may be limited to premenopausal women, particularly younger
premenopausal women.
However, our findings of different associations for childhood
body fatness with ovarian cancer risk by cohort could be partially
due to a cohort effect. Greater childhood body fatness among
women in the NHS may have been determined by different factors
than in the NHSII. Chance could also explain our results, given
Table 4 Multivariate
a relative risks (RR) and 95% confidence intervals (CI) of epithelial ovarian cancer according to childhood body fatness and BMI at the
age of 18 years, by menopausal status
Premenopausal (NHS and NHSII) Postmenopausal (NHS and NHSII)
Cases Person-years Multivariate
a RR (95% CI) Cases Person-years Multivariate
a RR (95% CI)
Average body fatness at the ages of 5 and 10 years
b
1 25 239481 1.0 (REF) 123 250962 1.0 (REF)
1.5–2 44 422079 1.16 (0.71–1.90) 96 232530 0.89 (0.68–1.17)
2.5–3 32 345738 0.96 (0.57–1.64) 59 167233 0.79 (0.58–1.08)
3.5–4.5 31 281222 1.12 (0.65–1.90) 38 142234 0.60 (0.42–0.87)
X5 13 85055 1.38 (0.70–2.71) 24 60158 0.85 (0.54–1.31)
P for trend
c 0.92 0.09
P for interaction¼0.37
BMI at the age of 18 years, kgm
 2
o20 64 657807 1.0 (REF) 172 446874 1.0 (REF)
20–20.9 38 313846 1.22 (0.81–1.83) 81 236512 0.90 (0.69–1.18)
21–22.9 53 401364 1.22 (0.84–1.77) 125 322686 1.04 (0.83–1.32)
23–24.9 26 183682 1.40 (0.88–2.21) 61 153997 1.04 (0.78–1.40)
X25 26 170607 1.41 (0.89–2.24) 43 123277 0.91 (0.65–1.27)
P for trend
d 0.10 0.85
P for interaction¼0.11
aMultivariate analyses adjusted for age (continuous), parity (continuous), duration of oral contraceptive use (continuous), tubal ligation history (yes/no), and height (o1.6, 1.6 to
o1.65, 1.65 to o1.7, 1.7 to o1.75, and X1.75m).
bAverage childhood body fatness calculated by taking the average of each participant’s body fatness at the ages 5 and 10
years.
cP value from multivariate model with body fatness modelled as continuous variable.
dP value from multivariate model with BMI at the age of 18 years modelled as medians
of categories.
Table 5 Multivariate
a relative risks (RR) and 95% confidence intervals (CI) of epithelial ovarian cancer according to height and birthweight, by study
population
Nurses’ Health Study (NHS) Nurses’ Health Study II (NHSII) NHS and NHSII combined
Cases
Person-
years
Multivariate
a
RR (95% CI) Cases Person-years
Multivariate
a
RR (95% CI) Cases Person-years
Multivariate
a
RR (95% CI)
Height, m
o1.6 148 572360 1.0 (REF) 18 314588 1.0 (REF) 166 886961 1.0 (REF)
1.6 to o1.65 217 734892 1.16 (0.94–1.43) 36 448775 1.41 (0.80–2.49) 253 1183667 1.19 (0.98–1.45)
1.65 to o1.7 198 710542 1.11 (0.89–1.37) 35 452681 1.39 (0.78–2.47) 233 1163223 1.14 (0.93–1.39)
1.7 to o1.75 135 394339 1.39 (1.10–1.75) 32 308771 1.96 (1.10–3.50) 167 703111 1.46 (1.17–1.81)
X1.75 37 116768 1.27 (0.88–1.82) 16 129593 2.35 (1.19–4.63) 53 246361 1.43 (1.05–1.96)
P for trend
b 0.01 0.01 0.001
P for heterogeneity
c¼0.22
Birthweight, lbs
o5.5 13 34925 0.99 (0.55–1.78) 2 36519 0.68 (0.16–2.84) 15 71444 0.93 (0.54–1.60)
5.5–6.9 69 165868 1.08 (0.79–1.48) 29 303063 1.19 (0.74–1.92) 98 468931 1.11 (0.85–1.44)
7.0–8.4 101 248159 1.0 (REF) 45 527664 1.0 (REF) 146 775823 1.0 (REF)
X8.5 43 72412 1.32 (0.92–1.90) 12 149557 0.83 (0.44–1.58) 55 221969 1.17 (0.85–1.60)
P for trend
d 0.58 0.45 0.92
P for heterogeneity
c¼0.35
aMultivariate analyses for height adjusted for age (continuous), parity (continuous), duration of oral contraceptive use (continuous), tubal ligation history (yes/no), and body mass
index at the age of 18 years (o20, 20–20.9, 21–22.9, 23–24.9, and X25kgm
 2). Multivariate analyses for birthweight adjusted for same factors except height (o1.6, 1.6 to
o1.65, 1.65 to o1.7, 1.7 to o1.75, and X1.75m) instead of body mass index at the age of 18 years.
bP value from multivariate model with height modelled as medians of
categories.
cP for heterogeneity by cohort assessed using the DerSimonian and Laird random effects model.
dP value from multivariate model with birthweight categories
modelled as ordinal.
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modest and the trends were only marginally significant. However,
strong associations between childhood body fatness and risk of
breast cancer have been observed in previous studies, suggesting
that it may predict the risk of hormone-related cancers in women.
Further, previous studies have observed significant associations of
both adolescent and adult BMI with ovarian cancer risk, lending
plausibility to our findings.
The associations of body size in childhood with ovarian cancer
risk could be mediated through endogenous hormones (Risch,
1998; Lukanova and Kaaks, 2005), although epidemiological data
on the relation of endogenous hormones with ovarian cancer risk
are sparse and inconsistent (Eliassen and Hankinson, 2008).
Obesity during adolescence has been associated with polycystic
ovary syndrome (PCOS), which is characterised by elevated levels
of luteinising hormone (LH) and possibly increased risk of ovarian
cancer (Schildkraut et al, 1996). Paradoxically, although, adiposity
in premenopausal women without PCOS (Cramer et al, 2002)
and postmenopausal women (Malacara et al, 2001) has been
related to lower LH levels. Obesity in pre-adolescent and
adolescent girls is associated with hyperinsulinemia and increased
production of androgens (Stoll, 1998), which may be related to
ovarian cancer risk (Risch, 1998). Also, lower levels of progester-
one could increase risk (Risch, 1998). Obesity in adolescence is
associated with increased risk of ovulatory infertility in adulthood
(Stoll, 1998), which leads to decreased progesterone levels, and
infertility has been associated with a modest increase in ovarian
cancer risk (Tworoger et al, 2007a). Clearly, more research is
needed to clarify the biological mechanisms underlying these
associations.
The observed positive association between height and ovarian
cancer risk is consistent with results from previous studies in
several populations (Rodriguez et al, 2002; Engeland et al, 2003;
Schouten et al, 2003, 2008). Interestingly, the positive association
for height has been restricted to or stronger among younger or
premenopausal women (Kuper et al, 2002; Lukanova et al, 2002;
Engeland et al, 2003; Schouten et al, 2008), consistent with our
findings. It is also possible that the difference in the observed
association for height in the NHS and the NHSII could be due to a
cohort effect.
Despite consistency across epidemiological studies, the biologi-
cal mechanisms explaining the observed associations for height are
unclear. Adult height may be a marker for genetic factors or of
energy intake, caloric restriction, or exposure to sex and growth
hormones in early life (Schouten et al, 2003). Height consistently
has been associated with risk of other cancers (Gunnell et al, 2001),
and the growth hormone/insulin-like growth factor (IGF) axis is a
potential pathway (Gunnell, 2000). However, epidemiological
studies of circulating levels of IGF and ovarian cancer risk are
inconclusive (Tworoger et al, 2007b), and thus other mechanisms
may be involved.
There are almost no epidemiological data on the relation of
birthweight to risk of ovarian cancer. In a small retrospective
medical record review, birthweight was not associated with
mortality from ovarian cancer, but greater weight gain in the
first year of life was associated with increased mortality (Barker
et al, 1995). The investigators hypothesised that patterns of
gonadotropin release are established in utero and during infancy,
and that this could influence ovarian cancer pathogenesis later in
life. A population-based case–control study found no overall
association between birthweight and ovarian cancer risk, although
among women younger than the age of 55 years, there was
a decreased risk of ovarian cancer for those who weighed o5.5
pounds at birth compared to those who weighed 5.5–9 pounds
(Rossing et al, 2008). Our findings do not support an association
of birthweight with ovarian cancer risk, although this should be
confirmed in other populations.
Our study has several limitations. Although we combined data
from two large cohort studies, we had limited power to examine
interactions or variation by histological type. Another limitation is
the reliance on recall of body size in early life. Important strengths
of our study include its large sample size, its prospective design,
the confirmation of ovarian cancer cases, and the detailed
information on menopausal status and ovarian cancer risk factors.
In summary, this study suggests that body fatness during
childhood and adult height may be related to ovarian cancer risk,
and that these associations may vary by menopausal status or age.
This is the first study to examine the associations of body fatness
during childhood with ovarian cancer risk, and it is one of the
largest, most comprehensive studies of the other body size
measures to date. Further research should confirm these findings
in other populations as well as examine the underlying biological
mechanisms.
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